You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
潤都股份(002923.SZ):伏立康唑原料藥獲得CEP證書
格隆匯 07-08 18:22

格隆匯7月8日丨潤都股份(002923.SZ)公佈,公司近日收到歐洲藥品質量管理局(以下簡稱"EDQM")簽發的關於伏立康唑原料藥歐洲藥典適用性證書(Certificate of Suitability to Monograph of European Pharmacopoeia,以下簡稱"CEP證書")。

本品是由美國輝瑞研發的一種廣譜三唑類抗真菌藥物;其作用機制是抑制真菌中由細胞色素P450介導的14α-甾醇去甲基化,從而抑制麥角甾醇的生物合成。體外試驗表明伏立康唑具有廣譜抗真菌作用。臨牀試驗表明,伏立康唑對念珠菌屬具有抗菌作用,對麴黴屬真菌有殺菌作用。此外,伏立康唑在體外對其他致病性真菌也有殺菌作用,包括對現有抗真菌藥敏感性較低的菌屬。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account